Ribometrix, Genentech partner for RNA-targeting small moleculesRibometrix Inc. and the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) are partnering to develop small molecules against undisclosed...

Blueprint gains broader FDA label for Gavreto FDA approved Gavreto pralsetinib from Blueprint Medicines Corp. (NASDA:BLUE) to treat advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion-positive, radioactive iodine-refractory thyroid cancer in patients at...

As investor enthusiasm for blood-based cancer screening soars in the wake of Grail’s $8 billion acquisition,  much of the activity is taking place in China, where a short list of dominant cancers, out-of-pocket spending habits...

Bucking ODAC recommendation, FDA wants another trial from MesoblastMesoblast Ltd. (ASX:MSB; NASDAQ:MESO) said FDA issued a complete response letter to a BLA for remestemcel-L to treat pediatric steroid-refractory acute GvHD. FDA’s Oncologic Drugs Advisory Committee had voted 9...

While CBMG’s $383 million take private deal was put in motion before U.S. officials further ratcheted up pressure on U.S- listed Chinese companies, the move highlights the trade-offs Chinese companies face in considering where to...

Three of four life sciences IPOs priced above expectations ahead of Friday’s session, and two biotechs in the group -- Forma and Repare -- posted big gains in their first trading day, showing continued strength...

Royalty Pharma priced the year’s second-largest biopharma IPO to date and then saw its shares rise nearly 60%, the latest sign of a robust appetite for fresh paper from life sciences companies. The investment firm’s...

Following last week’s IPO market performance, which saw three biotechs raise more than $740 million, a trio of preclinical companies are now preparing for their at bat. The IPO queue also gained five more companies...

Closely-watched CAR T company Legend raised more than $400 million Friday in the year's largest biotech IPO thus far. The deal helped push the total raised via life sciences IPOs to $6.2 billion, outpacing the...